statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease NeuroSense and Genetika+ Initiate Precision Medicine...

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting NeuroSense Presents Positive Data...

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April...

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private...

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics NeuroSense Collaborates with Lonza to Identify...

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE, Mass., April...

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire CAMBRIDGE, Mass...

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Feb. 7, 2024 CAMBRIDGE, Mass., Feb. 7...

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics (NASDAQ:NRSN  Get Free Report) and China Health Industries (OTCMKTS:CHHE  Get Free Report) are both medical companies, but which is the better business? We will...

NeuroSense Therapeutics (NASDAQ:NRSN) versus China Health Industries (OTCMKTS:CHHE) Financial Survey

NeuroSense Therapeutics (NASDAQ:NRSN  Get Free Report) and China Health Industries (OTCMKTS:CHHE  Get Free Report) are both medical companies, but which is the superior investment? We...

Critical Comparison: NeuroSense Therapeutics (NASDAQ:NRSN) versus China Health Industries (OTCMKTS:CHHE)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Volume	139,169.00
52-Wk High	$2.33
52-Wk Low	$0.40

NRSN NeuroSense Therapeutics Ltd

About

Feed

News

Fundamentals